

The 8th International Electronic Conference on Medicinal Chemistry (ECMC 2022) 01–30 NOVEMBER 2022 | ONLINE

# Quaternization of fluoroquinolones – novel permanently ionized antibacterials active against biofilms

Chaired by **DR. ALFREDO BERZAL-HERRANZ**; Co-Chaired by **PROF. DR. MARIA EMÍLIA SOUSA** 





#### Joanna Fedorowicz <sup>1,\*</sup>, Laura Turzyńska <sup>1</sup>, Cristina Durante-Cruz <sup>2</sup>, Heidi Mäkkylä <sup>2</sup>, Polina Ilina <sup>2</sup>, Krzesimir Ciura <sup>3</sup>, Anita Kornicka <sup>1</sup>, Päivi Tammela <sup>2</sup>, and Jarosław Sączewski <sup>4</sup>

<sup>1</sup> Department of Chemical Technology of Drugs, Faculty of Pharmacy, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland;

<sup>2</sup> Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, P.O. Box
56 (Viikinkaari 5 E), 00014 Helsinki, Finland;

<sup>3</sup> Department of Physical Chemistry, Medical University of Gdańsk, Al. Gen. Hallera 107, 80-416 Gdańsk, Poland;


<sup>4</sup> Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland.

\* Corresponding author: jfedorowicz@gumed.edu.pl



1

## Quaternization of fluoroquinolones – novel permanently ionized antibacterials active against biofilms



#### Abstract:

Increasing antimicrobial resistance poses a critical problem to public health. Many strategies are engaged to combat this problem; one of them is the synthesis of hybrid drugs consisting of diverse bioactive parts merged into one molecule. The risk that bacteria will mutate and evolve defense mechanisms is lower since the various pharmacophoric parts act against different molecular targets.


We developed a new class of fluoroquinolone-quaternary ammonium conjugates to obtain inhibitors of bacterial topoisomerases with membrane destabilization activity. Docking studies revealed that compounds can interact with topoisomerases in the fluoroquinolone-binding mode. Hybrids were screened against Gram-positive and negative bacteria, including pathogens from the ESKAPE group and antibiotic-resistant strains, in planktonic and biofilm forms. The most effective were moderately lipophilic (CHI 10-20) cyclopropyl-substituted molecules. Moreover, novel compounds exhibit negligible cytotoxicity.

Keywords: Antibacterial activity; Drug synthesis; Molecular docking; Quinolone, QAC

ECMC 2022

## Introduction


Antimicrobial resistance is one of the most threatening problems of global concern. The hardest to combat are multidrug-resistant ESKAPE pathogens due to their ability to form antibiotic-tolerant biofilms.



These facts highlight the need for а renewed research effort both the by academia and pharmaceutical industry in the fight against antibiotic resistance.

Antibiotic resistance first described

In the study, a series of novel dimethyl quaternary ammonium fluoroquinolone (FQ) derivatives **1a-h** was designed, synthesized and evaluated in terms of their antibacterial, cytotoxic, and physicochemical properties.



The tested Gram-positive and Gram-negative pathogenic strains, *i.e. Staphylococcus aureus* and *Pseudomonas aeruginosa*, were sensitive to the majority of the obtained compounds. Derivatives **1e** and **1g**, N<sup>+</sup>-dimethyl analogues of ciprofloxacin, displayed broad-spectrum activity with minimum inhibitory concentrations (MIC) of 6.25  $\mu$ M both selected towards bacteria, while ciprofloxacin hybrid compound **2d** showed slightly weaker effectiveness (MIC of 25  $\mu$ M).

N<sup>+</sup>-dimethyl quaternary gatifloxacin derivative **1f** was selective against Gram-positive strain (MIC of 6.25  $\mu$ M).


MIC [μM] Compound	Pseudomonas aeruginosa ATCC 27853	Staphylococcus aureus ATCC 29213
1b	>50	50
1c	>50	25
1d	75	25
1e	6.25	6.25
1f	>50	6.25
1g	6.25	6.25
1h	>50	50
2d	25	25
Ciprofloxacin hydrochloride	2.72	1.36




ECMC


2022

Moreover, the bioactive compounds **1e-g** and **2d** were found to be potent against biofilm in pre- and post-exposure tests with minimum biofilm inhibitory concentrations of 25  $\mu$ M (**1e**,**g**) against *P. aeruginosa* and 5 (**1f**) or 10  $\mu$ M (**1e**,**g**) towards *S. aureus*.



Furthermore, the molecular docking studies indicated that all the synthesized compounds interact in the FQ-binding mode at the active sites of bacterial type II topoisomerases and are able to inhibit the enzymes.





Selectivity of the active molecules towards bacterial cells was confirmed in cytotoxicity experiments that involved noncancerous cell lines (BALB/3T3 murine embryonic fibroblasts).

IC <sub>50</sub> [μM] Compound	BALB/3T3
1e	>200
1f	>200
1g	>200
2d	159.92 ± 9.23
Ciprofloxacin hydrochloride	>200

#### ECMC 2022 01–30 NOVEMBER 2022 | ONLINE Conference on Medicinal Chemistry

### Conclusions

Analysis of the structure-activity relationships (SAR) suggests that the lipophilic cyclopropyl group present within the N1 position of the FQ scaffold was essential for preserving pronounced antibacterial action, whereas quaternization of the terminal nitrogen atom at aliphatic diamine in the N7 position was not detrimental to bioactivity. The above remark was further supported by data obtained with the use of immobilized artificial membrane chromatography (IAM-HPLC), since phospholipophilicity indices (CHI) of the highest active derivatives were in the range of 11.7-18.23. The value determined for ciprofloxacin, the reference drug, was marginally upper or comparable (19.7).

This outcome is principally compelling, as the classic equilibrium-driven interconversion among uncharged and ionized species is absent in the case of studied quaternary FQs. It proves the potential for novel antibacterials development and provides insights into the SAR of antibacterial agents derived from FQs. The described FQ-based compounds might be a promising starting point for the rational design of well-tolerated and highly potent antibiotics.

## есмс 2022

## Acknowledgments

We thank OpenEye Scientific Software, Santa Fe, NM., for free academic licenses for the use of their software, and the DDCB core facility supported by the University of Helsinki (HiLIFE) and Biocenter Finland for access to bioactivity screening facilities.

The Project was financed by the Polish National Agency for Academic Exchange as a part of the Bekker Scholarship Programme.



